Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson&rs...
In an interaction with BioPharma BoardRoom, Saurabh Singal, CEO & Founder of MoleculeAI, discusses how their generative AI-driven tools...
HUB internationally recognized pioneer in organoid development Acquisition expands Merck’s 2D and 3D cell culture portfolio Organ...
Viatris Inc. (NASDAQ: VTRS) announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of ceneri...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has received CE mark approval for its cobas® Mass Spec solution including the cobas® i 601 ana...
Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) in China has approved Kisunla...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics L...
Sandoz takes further steps to resolve legacy US generic drug antitrust class action litigation Sandoz US has entered into a settlement agreement with ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programs for vibostolima...
Jaypirca®, a highly selective kinase inhibitor, utilizes a novel non-covalent binding mechanism to re-establish BTK inhibition in mantle cell lymphoma ...
Positive CHMP opinion brings us closer to offering WELIREG, a first-in-class HIF-2α inhibitor, to certain patients in the European Union, in order to...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., shared new data ...
Matt Boag, Biopharmaceutical Product Marketing Manager at Phenomenex, discusses the transformative innovations shaping plasmid DNA, mRNA, and peptide purif...
Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT0...
© 2024 Biopharma Boardroom. All Rights Reserved.
